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ABSTRACT
Background: Endovascular repair of aortic diseases is a 
well-established therapeutic alternative for patients with the 
appropriate anatomy and/or high surgical risk, as it provides 
lower morbidity and mortality rates. This study aimed to 
analyse the outcomes of asymptomatic patients undergoing 
endovascular treatment of thoracic aortic dissections with an 
aortic diameter >  5.5  cm or endoleaks. Technical success, 
therapeutic success, morbidity, mortality, and perioperative 
complication and reintervention rates were assessed. Methods: 
The present retrospective study, which was performed at a 
reference centre from January, 2010 to July, 2011, anal-
ysed consecutive patients undergoing endovascular repair 
of chronic complicated type B aortic dissections based on 
the Stanford classification. Results: Twenty-six patients were 
treated. The mean age was 56.4 ± 7 years, and 61.5% were 
males. Technical and therapeutic success rates were 100% 
and 74%, respectively. The perioperative mortality was 7.6%, 
and the mortality rate in the first year of follow-up was 
19.3%. The reintervention rate was 15.3%. Conclusions: In 
the present study, endovascular treatment of chronic type 
B aortic dissections proved to be a feasible method associ-
ated with acceptable perioperative complication rates. The 
therapeutic success and reintervention rates indicated the 
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RESUMO
Tratamento Endovascular da Dissecção Crônica  
de Aorta Tipo B Complicada
Introdução: A correção endovascular das doenças aórticas está 
bem estabelecida como alternativa terapêutica para pacientes com 
anatomia adequada e/ou alto risco cirúrgico, proporcionando 
menores taxas de morbidade e mortalidade. Nosso objetivo foi 
analisar os resultados do tratamento de pacientes assintomáticos 
submetidos a tratamento endo-vascular de dissecções de aorta 
torácica complicadas, seja por diâmetro aórtico > 5,5 cm ou 
vazamentos. Avaliamos o sucesso técnico, o sucesso terapêutico, 
a morbidade e a mortalidade, e as taxas de complicações peri-
operatórias e de reintervenções. Métodos: Estudo retrospectivo, 
realizado em um centro de referência, no período de janeiro 
de 2010 a julho de 2011, em que foram analisados pacientes 
consecuti-vos submetidos a correção endovascular de dissecção 
crônica de aorta tipo B complicada pela classificação de Stanford. 
Resultados: Foram tratados 26 pacientes. A média de idade foi 
de 56,4 ± 7 anos e 61,5% eram do sexo masculino. Os sucessos 
técnico e terapêutico foram de 100% e 74%, res-pectivamente. 
A mortalidade perioperatória foi de 7,6% e a taxa de mortali-
dade no primeiro ano de seguimento foi de 19,3%. A taxa de 
reintervenção foi de 15,3%. Conclusões: Em nosso estudo, o 
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necessity for stringent and careful clinical follow-up of these 
patients.
 
 
 
DESCRIPTORS: Dissection. Aorta, thoracic. Prostheses and 
implants. Atherosclerosis.
S tanford type B aortic dissection, which does not involve the ascending aorta, causes high rates of morbidity and mortality in its complicated form, 
occurring in younger patients and resulting in death from 
direct complications of the disease.1 Spontaneous reso-
lution is rare.2 The risk factors that are often associated 
with this disease include hypertension, cardiovascular 
disease, lung diseases, and kidney dysfunction. Stan-
ford type B aortic dissection predominates in the male 
gender (3:1), and approximately 30% of patients with 
type B dissections develop some type of complication.
Endovascular or surgical treatment is indicated when 
there is rapid increase in the aortic diameter, signs of 
rupture (mediastinal bruises, pleural effusion), ischaemic 
syndromes or intractable pain. In such situations, this 
intervention has superior results compared with clinical 
treatment.3 The overall mortality for surgical repair of 
type B aortic dissections is approximately 30%, reaching 
50% when surgery occurs in emergency situations.1,4,5
Endovascular devices allow for a treatment that is 
less invasive than surgery, preventing aortic clamping.6 
The stents occlude the dissection orifices, reorganise 
the vessel layers, and prevent blood entry between the 
vessel layers, leading to decompression, thrombosis, and 
fibrosis of the false lumen, thus contributing to favourable 
aortic remodelling and fewer adverse clinical events.3 
Endovascular treatment yields lower rates of blood trans-
fusion, shorter hospital stays, reduced length of intensive 
care unit stays, and lower costs. Moreover, this therapy 
allows for reperfusion of ischaemic vascular beds in 
complicated dissections, with lower risks than found in 
open surgery.7 The main disadvantage of this technique 
is that it predisposes the patient to an increased number 
of reinterventions in the medium- and long-term.8,9
Endovascular treatment of chronic type B aortic 
dissections is still controversial. The primary debate 
refers to the possibility of remodelling not occurring 
after occlusion of the inlet orifice, either because of the 
incapacity of the prosthesis to expand completely or due 
to the incapacity of the previously formed haematoma 
to be reabsorbed by the blood vessel wall.2
The aim of this study was to evaluate the clinical 
outcomes of asymptomatic patients undergoing endo-
vascular repair of complicated type B aortic dissections 
by analysing the technical success, therapeutic success, 
morbidity and mortality, complications, and rate of 
reinterventions.
tratamento endovascular da dissecção crônica de aorta tipo B 
demonstrou ser um método viável e associado a aceitáveis taxas 
de complicações perioperatórias. As taxas de sucesso terapêu-
tico e de reintervenções obtidas demonstram a necessidade de 
seguimento clínico rigoroso e atento desses pacientes.
DESCRITORES: Dissecação. Aorta torácica. Próteses e implantes. 
Aterosclerose.
METHODS
Study type
A retrospective, observational, longitudinal study 
was conducted at a reference centre for cardiovascular 
diseases from January of 2010 to July of 2011. In total, 
26 patients undergoing endovascular repair of type B 
aortic dissections were evaluated.
Inclusion and exclusion criteria
Patients with type B aortic dissections with aortic 
diameters ≥ 55 mm, as well as patients who were pre-
viously treated with stents that developed type I or III 
endoleaks, were included.
The study excluded patients with a proximal aortic 
neck containing thrombi or calcifications >  50% of the 
neck diameter, an external iliac artery diameter < 7 mm 
or a creatinine clearance < 30 mL/min.
A cardiac and/or anaesthetic risk assessment was not 
considered in the inclusion or exclusion of the patients. 
Surgical technique
All procedures were performed in the Haemody-
namics Laboratory of the Endovascular Intervention 
Centre (Centro de Intervenções Endovasculares – CIEV) 
of the Instituto Dante Pazzanese de Cardiologia (São 
Paulo, SP, Brazil).
For all cases, the diagnosis and treatment schedule 
were based on the angiotomography results; pre-operative 
arteriography was considered to be an optional diagnostic 
method. All of the tomography scans were reconstructed 
using OsiriX software version 3.2 for Macintosh (Depart-
ment of Medical Imaging and Information Science of the 
University Hospital of Geneva – Geneva, Switzerland) 
in three-dimensional mode and multiplanar reconstruc-
tion mode; subsequently, the diameters, as well as the 
dissection angles and extensions of the proximal and 
distal aortic neck of the aorta were obtained (Figure 1).
All patients received general inhalational anaes-
thesia with cerebrospinal fluid monitoring in cases of 
second treatment of aortic aneurysms and in cases in 
which preoperative carotid-subclavian or carotid-carotid 
bypasses were performed.
After anaesthesia induction and appropriate anti-
biotic prophylaxis (1.5  g cefuroxime), treatment was 
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initiated by open surgical dissection (unilateral) of the 
common femoral artery and by contralateral femoral or 
brachial puncture, based on the type of intervention 
being performed.
The radiographic control was performed using Artis 
flat panel equipment (Siemens – Erlangen, Germany). 
The following devices were used: Valiant® (Medtronic 
– Minneapolis, MN, USA), Zenith TX2® (Cook Medi-
cal – Bloomington, IN, USA), TAG® (Gore Medical – 
Flagstaff, AZ, USA), Hercules® (Microport – Shanghai, 
China), and Relay® (Bolton Medical – Sunrise, FL, USA). 
Intraoperative control arteriography was performed in 
all patients (Figure 2). The immediate postoperative 
period occurred in the intensive care unit in all cases.
Postoperative follow-up
All of the patients were followed for 15 days, 30 
days, 180 days, and 360 days after correction. In this 
study, angiotomographies performed 30 days after the 
intervention and at the end of the first year were ana-
lysed. Outpatient follow-up and annual tomographic 
images were maintained in all patients.
Outcomes and definitions
The following were considered to be primary 
outcomes:
– Technical success: when stent release occurred 
in the affected area, with or without the presence of 
endoleaks or other events that could adversely affect 
the development of aortic disease.
– Therapeutic success: when stent release occurred 
without leaks or other events that could promote the 
development of aortic disease.
– Perioperative mortality: considered to be all deaths 
recorded within the first 30 days after the procedure.
– Procedural complications: classified as intraopera-
tive (occurring in the catheterisation laboratory during 
the intervention) and in-hospital (occurring during hos-
pitalisation, outside the catheterisation laboratory, and 
within 30 days after the intervention). The following 
outcomes were considered to be complications: local 
bleeding (retroperitoneal or inguinal haematoma); in-
advertent occlusion of the subclavian artery; peripheral 
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Figure 1 – Angiotomography with multiplanar and three-dimensional reconstruction. A, axial view demonstrating entry of the dissection at the origin of 
the left subclavian artery. B, the largest aortic diameter. C, sagittal view. D, the superior mesenteric artery originating from the true lumen. E, abdominal 
aortic involvement. F, left iliac artery dissection. G, three-dimensional reconstruction in the left anterior oblique view. H, three-dimensional reconstruction 
in the right anterior oblique view.
Figure 2 – Endovascular repair of the Stanford type B dissection. 
A, intraoperative aortography demonstrating a Stanford type B dissection 
in a bovine type II aortic arch. B, endovascular repair of a Stanford 
type B aortic dissection with the presence of a type Ia endoleak.
A B
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embolisation to the lower limbs with acute arterial 
occlusion; occurrence of paraplegia or paraparesis; 
infections in the surgical site, lower respiratory tract, 
or stent; acute renal failure, defined as an increase 
>  two times the baseline creatinine level prior to the 
procedure; and death.
– Reintervention: interventions performed to main-
tain appropriate functioning of the stent or resolution 
of complications associated with the intervention.
The following were considered to be secondary 
outcomes: initial or primary endoleaks (originating 
during the initial procedure or diagnosed within the 
first 30 days) and secondary endoleaks (diagnosed 30 
days after the initial procedure).
The anchorage sites for the thoracic aortic endo-
prosthetic fixation were analysed based on the clas-
sification of Ishimaru.10
RESULTS
In total, 26 patients treated for type B aortic dis-
section were included, of whom 15 (57.6%) had treat-
ment indications due to diameters >  55  mm, and 11 
patients (42.3%) presented late endoleaks. The clinical 
and demographic characteristics of the study population 
are listed in Table 1.
All patients were asymptomatic and treated 
electively. The mean duration of the procedure was 
67 minutes (49 to 104 minutes), and the mean hos-
pital stay was 9.9 days, with an eight-day range. 
Inhalational anaesthesia was used in all cases, with 
cerebrospinal fluid monitoring in 14 cases (53.1%).
The anchorage sites for the thoracic aortic en-
doprosthetic fixation were distributed, based on the 
classification of Ishimaru,10 in six cases (23%) in zone 
2, 14 cases (53.8%) in zone 3, and six cases (23%), 
in zone 4. All of the patients with anchorage in zone 
2 underwent subclavian artery bypass surgery before 
the procedure.
The devices used were Valiant® in 10 cases (38.5%), 
Zenith TX2® in seven cases (27%), TAG® in six cases 
(23%), Relay® stent in two cases (7.6%), and Hercules® 
in one case (3.8%).
Technical success was achieved in all cases. 
Therapeutic success occurred in 20 patients (74%). The 
only cause of treatment failure was the occurrence or 
persistence of an endoleak, based on the intervention 
indication. Of the six patients who did not achieve 
initial therapeutic success, four (15.4%) were from the 
second treatment group, and two (7.6%) were from the 
primary treatment group.
The complication rate was 30.7%, and the most 
frequent intraoperative complications were femoral artery 
lesions in two patients (7.6%) and inadvertent occlusion of 
the subclavian artery in one patient (3.8%). The in-hospital 
postoperative complications consisted of surgical site infec-
tion in two patients (7.6%), retroperitoneal haematoma 
in one patient (3.8%), acute kidney failure in one patient 
(3.8%), and one case (3.8%) of paraplegia in a patient 
who had undergone a preoperative carotid-subclavian 
bypass and selective cerebrospinal fluid drainage (Table 2).
TABLE 1  
Demographic Characteristics and Clinical  
Data of the Study Population
n = 26
Mean age, years 56.4 ± 7
Male gender, n (%) 16 (61.5)
Asymptomatic disease, n (%) 26 (100)
Morbid obesity (BMI > 40 kg/m2), n (%) 2 (7.6)
Smoker (current smoker or nonsmoker  
for the last 12 months), n (%)
12 (46.1)
Diabetes mellitus, n (%) 6 (23)
Hypertension, n (%) 26 (100)
Dyslipidaemia, n (%) 9 (34.6)
Chronic kidney disease, n (%) 3 (11.5)
Heart failure, n (%) 3 (11.5)
Chronic obstructive pulmonary  
disease, n (%)
1 (3.8)
Previous aortic surgery, n (%) 12 (46.1)
Stroke, n (%) 7 (26.9)
Congestive heart failure, n (%) 1 (3.8)
BMI = body mass index; n = number of patients.
TABLE 2 
Analysis of Intra- and Perioperative Complications
n = 26
Intraoperative complications, n (%)
 Peripheral embolisation 1 (3.8)
 Femoral lesion 2 (7.6)
 Subclavian occlusion 1 (3.8)
In-hospital complications, n (%)
 Paraplegia 1 (3.8)
 Infection 2 (7.6)
 Retroperitoneal haematoma 1 (3.8)
 Acute kidney failure 1 (3.8)
 Death 2 (7.6)
n = number of patients.
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The total rate of primary endoleaks was 23%, and all 
of the cases were type Ia. There were no cases of type II 
or III endoleaks or of stent migration during the patient 
follow-up. Two high-risk surgical patients presented sponta-
neous resolution of the leaks within three and six months 
of computed tomography follow-up, respectively. The 
reintervention rate in one year was 15.3%, resulting 
from treatment of type I leaks.
Perioperative mortality was 7.6% (n = 2), with one 
death secondary to sepsis from a lower respiratory tract 
infection and the other death due to cardiopulmonary 
arrest secondary to Chagas cardiomyopathy. At the one-
year follow-up, three additional deaths were observed: 
two cases of aortic redissection (at three months and four 
months after surgery), and one patient with ischaemic 
cardiomyopathy who progressed to acute pulmonary 
oedema (11 months after the procedure). The annual 
survival rate during follow-up was 80.7%.
DISCUSSION
Endovascular treatment of thoracic aortic disease is 
currently the treatment of choice for selected cases.1,3,11 
Although acknowledged, the procedure yields variable 
results that depend on the analysed population. The 
anatomical and physiopathological differences be-
tween aneurysms and aortic dissections affect surgical 
techniques, translating into different results. Due to 
the instability and frailty of the aortic wall in thoracic 
aortic dissections, proper occlusion of the inlet might 
not be effectively achieved. In patients with aneurysms, 
anatomic distortion (characterised by increased tortuosity 
of the aortic arch), and a higher incidence of peripheral 
atherosclerotic stenoses often limit the efficacy of the 
release system.
The technical success rate in the present study was 
100%, that is, the stent was positioned and released 
at the desired site in all cases. Brazilian authors have 
demonstrated technical success rates of 98% in 130 
patients treated for type B aortic dissection and true 
aneurysms.12 The EUROpean collaborators on Stent-graft 
Techniques for abdominal aortic Aneurysm Repair (EU-
ROSTAR)13 study observed a primary technical success 
rate of 89% in patients with aortic dissections.
The therapeutic success rate in the present study 
was 73%, due to the presence of only type I endoleaks. 
This type of leak is the most frequent complication 
associated with endovascular repair of aortic dissec-
tions, and can eventually result in clinical failure. The 
percentages reported in the literature range from 0% to 
44%.14–16 In this study population, the rate of primary 
leaks was 23%. An inlet less than 2  cm from the left 
subclavian artery and located in the lesser curvature 
of the aortic arch is one of the factors predisposing 
to stent kinking and leaks during control angiography, 
as well as previous aortic surgical or endovascular 
manipulation. In the present study, 11 patients (42.3%) 
exhibited leaks as indications for the endovascular pro-
cedure, of which four patients had undergone previous 
aortic surgery and seven patients had undergone prior 
endovascular treatment.
Of the patients with type I endoleaks, two individu-
als presented a small leak volume during arteriography, 
which resolved spontaneously within three to six months 
of follow-up. These data suggest better rates of thera-
peutic success without hasty interventions, as well as 
fewer future reinterventions.
There were no cases of secondary leaks. Conside ring 
the cases with spontaneous resolution, the reintervention 
rate was 15.3% at the one-year follow-up. The ‘sponta-
neous resolution’ of type I leaks is actually caused by 
thrombosis of small leaks, which can evolve with the 
continuous transmission of pressure to the false lumen. 
The Evaluation of the Medtronic Vascular Talent Thoracic 
Stent Graft System for the Treatment of Thoracic Aortic 
Aneurysms (VALOR) study17 demons trated annual leak 
rates of 17%, with type I leaks in 6.3%, type II leaks 
in 9.5%, and type III leaks in 1.9% of the cases.
In the present study, it was observed that the thera-
peutic success rate for the type Ia leak was lower than 
that for type Ib. Thus, only 43% of Ia leaks could be 
repaired. To explain these data, it was observed that 
23% of the endoprostheses were anchored in zone 2. 
All of these patients underwent a carotid-subclavian 
bypass. The coverage of the subclavian artery was 
generally well tolerated, and few patients developed 
dizziness or claudication of the left upper limb. In the 
VALOR study, 5% of the patients underwent a carotid-
subclavian bypass. Many groups electively perform this 
bypass, belatedly, in cases of symptom onset.17,18
A complication rate of 30.7% was observed in 
the present study; the femoral artery lesion was the 
most prevalent complication, in 7.6% of the cases. 
The large profile devices associated with the hight 
number of patients who underwent retreatment con-
tributed to these rates in the present study. The series 
published by the Arizona Heart Institute demonstrated 
complications in only 38% of patients with mild 
dissections.19 In the present study, one case of per-
manent paraplegia was (3.8%). There were no cases 
of stroke. Prophylactic cerebrospinal fluid drainage 
may be useful in high-risk patients, i.e., patients 
with diseases of the thoracic aorta and associated 
abdominal aorta, histories of open or endovascular 
repair of abdominal aortic aneurysms, requirements 
for iliac conduits to advance the stent due to a his-
tory of transient paralysis of the lower limbs, and the 
incapacity to undergo cerebrospinal fluid drainage 
in less than an hour after stent implantation if para-
paresis or paraplegia are expected. The main disad-
vantage of preoperative drainage is potential spinal 
haematoma formation administering heparin during 
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the intervention. In this case, the cerebrospinal fluid 
drainage should be suspended.20 In the present study, 
all patients submitted to a second treatment for repair 
of previous leaks and those patients who had been 
submitted to a previous surgical bypass underwent 
cerebrospinal fluid monitoring and drainage whenever 
increases in cerebrospinal fluid pressure levels were 
detected. In most series and comparisons between 
endovascular and surgical treatments for Stanford 
type B aortic dissections, endovascular treatment 
decreases the incidence of definitive paraplegia.21 
However, in centres of excellence in the treatment 
of dissection with rates of postoperative paraplegia 
< 5%, endovascular treatment might not be superior 
in this regard.11 Overall, permanent paraplegia occurs 
in approximately 2% to 3% of patients after endo-
vascular treatment. The EUROSTAR study revealed a 
0.8% incidence of paraplegia in patients undergoing 
endovascular treatment for aortic dissections.13
The perioperative mortality rate in the present study 
was 7.6%, with an annual survival rate of 80.7%. Thirty 
days after the intervention, three deaths had occurred: 
two cases due to redissection and one case due to 
acute pulmonary oedema. In the EUROSTAR study, 
the in-hospital mortality was 8.4% in patients treated 
for dissection, and the annual survival rate was 90%, 
whereas in the Arizona Heart Institute series, the survival 
rate was 85%.13,19 The present study demonstrated a sur-
vival rate similar to that reported in other publications.
Prophylactic endovascular treatment of patients with 
stable type B aortic dissections should not be prescribed. 
The INvestigation of STEnt Grafts in Aortic Dissection 
(INSTEAD) study compared the clinical or endovascular 
treatment of 140 patients with chronic, stable, and as-
ymptomatic dissections, and revealed no differences in 
mortality from any cause. The survival rate was 95.6% 
in the clinical treatment group vs. 88.9% in the en-
dovascular treatment group at the two-year follow-up. 
The progression and death caused by rupture was 
similar in both groups, while the aortic remodelling 
was 91.3% in patients from the endovascular treat-
ment group vs. 19.4% in the clinical treatment group. 
However, the clinical follow-up showed a significant 
number of patients who had to migrate to endovascular 
treatment.22 In patients such as of the present study, i.e., 
symptomatic patients with complications (malperfusion 
syndrome, progression of dissection, increased aneu-
rysmal dilation, and impaired blood pressure control), 
the indication for endovascular treatment is already 
established in the literature.21,23
Concerning the group with chronic type B dis-
sections, the literature also raises questions about the 
long-term survival of these patients, as well as the 
need for endovascular treatment of aortic remodelling. 
Moreover, questions have been raised about the endo-
vascular treatment of type B dissections in patients with 
Marfan syndrome. Regarding this type of correction, 
there are concerns about the capacity of the diseased 
vessel to withstand the radial force of the device, which 
might cause additional dilation or dissection of juxta-
implant segments. No evidence has yet confirmed this 
hypothesis, but the recommended precautions include 
avoiding the use of oversized prostheses, post-dilatation 
balloons, or uncoated stents in the extremities. In the 
present study, no patients had Marfan syndrome. The 
surprising scarcity of reports regarding patients with this 
syndrome (especially in cases with acute dissection) 
in the published series on endovascular treatment of 
thoracic diseases might demonstrate a group selection 
bias that is related to poor initial results.24
Study limitations
The limitations of this study included the small 
number of patients analysed, its retrospective nature 
and the lack of a comparative control group of patients 
with chronic type B dissections who were clinically 
treated. These factors limit the conclusions drawn and 
the comparison with larger studies.
The inclusion of patients in the second treatment 
due to endoleaks worsened the acute results of the 
total series, as the success rate was lower in this group.
CONCLUSIONS
In the present study, endovascular treatment of 
complicated, chronic, type B aortic dissections proved 
to be a feasible method associated with acceptable rates 
of perioperative complications. The rates of therapeutic 
success and reinterventions that were attained demon-
strate the requirement for stringent and careful clinical 
follow-up of these patients.
The long-term benefit of endovascular therapy for 
complicated, chronic, type B aortic dissection is the 
major challenge to be achieved. Further studies are 
necessary to better assess this benefit.
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